89bio to Participate in Upcoming Investor Conferences
89bio, a clinical-stage biopharmaceutical company focusing on innovative therapies for liver and cardio-metabolic diseases, has announced its participation in several investor conferences this June.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
89bio, a clinical-stage biopharmaceutical company focusing on innovative therapies for liver and cardio-metabolic diseases, has announced its participation in several investor conferences this June.
- SVB Leerink CybeRx Series: Liver Disease Day - One-on-one meetings on June 17, 2021.
- Raymond James Human Health Innovation Conference - Panel discussion on NASH on June 23, 2021, at 12:00 PM ET.
- Piper Sandler EASL Takeaway Day - One-on-one meetings on June 28, 2021.
The company’s leading product candidate is BIO89-100, targeting NASH and severe hypertriglyceridemia.
Details
News Market Reaction – ETNB
The recorded move for ETNB in the trading session of this news was +0.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in the following upcoming investor conferences in June:
- SVB Leerink CybeRx Series: Liver Disease Day
Format: One-on-one investor meetings
Date: Thursday, June 17, 2021
- Raymond James Human Health Innovation Conference
Panel Discussion: “State” of the Union: Current Thinking in NASH
Date: Wednesday, June 23, 2021 at 12:00 PM ET
- Piper Sandler EASL Takeaway Day
Format: One-on-one investor meetings
Date: Monday, June 28, 2021
About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com
Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.